Last reviewed · How we verify
discontinuation of oxytocin administration
discontinuation of oxytocin administration is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Management of labor induction or augmentation when continuation is no longer clinically indicated, Reduction of postpartum hemorrhage risk when oxytocin infusion is no longer needed.
Discontinuation of oxytocin administration removes the exogenous hormone that stimulates uterine contractions and milk letdown.
Discontinuation of oxytocin administration removes the exogenous hormone that stimulates uterine contractions and milk letdown. Used for Management of labor induction or augmentation when continuation is no longer clinically indicated, Reduction of postpartum hemorrhage risk when oxytocin infusion is no longer needed.
At a glance
| Generic name | discontinuation of oxytocin administration |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Oxytocin is a naturally occurring hormone used clinically to induce or augment labor and to control postpartum hemorrhage. Discontinuing its administration allows the exogenous stimulus to uterine smooth muscle contraction to cease, permitting the uterus to return to baseline contractility. This is a procedural intervention rather than a pharmacological agent with a specific molecular mechanism.
Approved indications
- Management of labor induction or augmentation when continuation is no longer clinically indicated
- Reduction of postpartum hemorrhage risk when oxytocin infusion is no longer needed
Common side effects
Key clinical trials
- Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor (PHASE4)
- The Role of Oxytocin in the Second Stage of Labor (NA)
- The Influence of Oxytocin on Intrapartum Fetal Well-being and Delivery Outcomes in Patients Receiving Epidural Analgesia (NA)
- Continued Versus Discontinued Oxytocin Stimulation of Labour (PHASE4)
- A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- discontinuation of oxytocin administration CI brief — competitive landscape report
- discontinuation of oxytocin administration updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about discontinuation of oxytocin administration
What is discontinuation of oxytocin administration?
How does discontinuation of oxytocin administration work?
What is discontinuation of oxytocin administration used for?
Who makes discontinuation of oxytocin administration?
What development phase is discontinuation of oxytocin administration in?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Obstetrics
- Indication: Drugs for Management of labor induction or augmentation when continuation is no longer clinically indicated
- Indication: Drugs for Reduction of postpartum hemorrhage risk when oxytocin infusion is no longer needed
- Compare: discontinuation of oxytocin administration vs similar drugs
- Pricing: discontinuation of oxytocin administration cost, discount & access